Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004488 · ClinicalTrials.gov registry record · Phase 2
Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease
A Phase 2 study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
NCT00004488 is a Phase 2 study that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 82 participants.
The verdict
NCT00004488, a Phase 2 study, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
Study Summary
OBJECTIVES: I. Determine the efficacy of alendronate sodium in treating osteopenia (generalized bone density and focal bone lesions) in patients with Gaucher's disease.
Interventions
- DRUG alendronate sodium
- DRUG cholecalciferol
- DRUG calcium carbonate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 1998-10 |
| Est. Completion | 2002-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004488
The ClinicalTrials.gov registry entry for NCT00004488 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which alendronate sodium is the first listed.
NCT00004488 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004488 about?
NCT00004488 is a clinical study titled "Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease". OBJECTIVES: I. Determine the efficacy of alendronate sodium in treating osteopenia (generalized bone density and focal bone lesions) in patients with Gaucher's disease.
What is the current status of trial NCT00004488?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 1998-10. Estimated completion is 2002-09.
What interventions are being tested in trial NCT00004488?
The interventions under investigation include: alendronate sodium (DRUG), cholecalciferol (DRUG), calcium carbonate (DRUG).
Who is sponsoring clinical trial NCT00004488?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.